Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety Study of Insulin Detemir in Diabetes (PREDICTIVE)
NCT01709929Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Oct 2005
- Primary completion
- Apr 2006
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of insulin detemir in type 1 diabetes mellitus (T1D) and type 2 diabetes mellitus (T2DM), sponsored by Novo Nordisk. Primary endpoint: Incidence of serious adverse drug reactions. Started Oct 2005; status: completed.
02
Drugs
insulin detemir
03
Conditions
type 1 diabetes mellitus (T1D)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01709929.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01709929.